Answers are grounded in this paper and cite their sources.
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder in which, epithelial cells are somehow dedifferentiated but highly proliferative and form renal cysts.There are also proliferative CD133+ renal progenitor cells in an ADPKD kidney.Among several therapeutic strategies that exist to heal ADPKD, bone marrow mesenchymal stem cells (BM-MSC) are of great interest.So, we examined human BM-MSC-condition medium (hBM-MSC-CM) effects on polycystic CD133+ renal progenitor cells.For this purpose, polycystic CD133+ renal progenitor cells were isolated from patients undergoing nephrectomy for kidney transplantation.Differentiation and cystogenic potentials of polycystic CD133+ renal progenitor cells were evaluated using hBM-MSC-CM.Polycystic-lining cells expressed CD133 as a renal progenitor cell marker.These cells were more proliferative and presented a defective epithelial differentiation phenotype compared to normal kidney CD133+ renal progenitor cells.Also, they were not able to express differentiated tubular epithelial cell markers such as E-cadherin and ZO-1.Moreover, polycystic CD133+ renal progenitor cells, in contrast to normal CD133+ renal progenitor cells, formed cysts in a three-dimensional (3D) culture system.hBM-MSC-CM treatment decreased proliferation and cystogenesis, but increased differentiation of polycystic CD133+ renal progenitor cells in vitro.All in all, hBM-MSC-CM could decrease the proliferation and cystogenesis through induction of differentiation in polycystic CD133+ renal progenitor cells.
No takes yet. Share an insight, caveat, or question.
Reza Moghadasali (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: